From GlobeNewswire: 2024-06-19 21:00:00

The Global Lenalidomide Drug Market is set to grow from USD 12.34 Billion in 2023 to USD 21.47 Billion by 2033, with a CAGR of 5.69% during the projected period. Lenalidomide is used to treat various cancers and boost immunity, driving market demand for its effectiveness in treating myelodysplastic syndromes and myeloma. The rising incidence of multiple myeloma worldwide and advancements in healthcare facilities contribute to the market’s expansion.

10mg capsules are anticipated to dominate the global lenalidomide drug market, offering patients a consistent and effective dosage. Among the various applications, multiple myeloma is expected to experience the fastest growth due to lenalidomide’s proven benefits in treating this cancer type. Hospitals are predicted to be the major end user for the lenalidomide drug market during the estimated period.

North America is projected to lead the global lenalidomide drug market, driven by the higher prevalence of multiple myeloma and myelodysplastic syndromes, along with a strong pharmaceutical industry investing in research and development. Asia Pacific is expected to witness rapid growth, attributed to factors such as rising cancer incidence and new product launches, like lenalidomide capsules in various strengths receiving FDA approval.

Key players in the global lenalidomide drug market include Celgene Corporation, Natco Pharma Limited, Mylan N.V., and Cipla Ltd. Recent developments include Cipla Limited receiving FDA approval for lenalidomide capsules and Aurobindo pharmaceutical company gaining approval to manufacture and market the drug. The competitive landscape involves strategic alliances, product innovations, and mergers & acquisitions among major vendors.



Read more at GlobeNewswire: Global Lenalidomide Drug Market Size To Worth USD 21.47